Comparative pharmacokinetic studies of Ephedra herba in common cold and nephrotic syndrome rat models
Journal of Separation Science · 2023
DOI: 10.1002/jssc.202200895 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Separation Science, 2023. Verfasst von Yumin Cao und 8 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Henan University of Chinese Medicine, Zhengzhou, P. R. China. Hauptthemen laut MEDLINE: Ephedra, Common Cold, Nephrotic Syndrome, Drugs, Chinese Herbal. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Youth Science Foundation Project in the National Natural Science Foundation of China, Henan science and technology development plan-Key R & D and promotion project.
Abstract (Originalsprache)
Ephedra herba is a conventional Chinese medicine to treat cold, fever, asthma, edema, and lung diseases in the clinic. At present, most pharmacokinetic studies focus on the pharmacokinetic process of alkaloids in normal animals. However, the non‐alkaloid components are also active. In addition, the pharmacokinetic studies under pathological state make more sense for clarifying the material basis of efficacy. In this study, a sensitive and rapid ultra‐high‐performance–tandem mass spectrometry method was developed and applied to determine nine bioactive components (ephedrine, pseudoephedrine, methylephedrine, (+)‐catechin, epicatechin, vitexin, vicenin‐2, cinnamic acid, and ferulic acid) in normal, common cold and nephrotic syndrome rats after the oral administration of Ephedra herba. Compared to the normal group, except for ferulic acid, the exposure levels of the other eight components were significantly increased and the plasma clearance clearly declined in common cold rats. Similarly, the exposure levels of seven components other than cinnamic acid and ferulic acid were also significantly augmented and the plasma clearance decreased significantly in nephrotic syndrome rats. In brief, the pathological conditions of the common cold and nephrotic syndrome could lead to alterations in the pharmacokinetics profiles of the nine components, which provide a reference for further exploration of the pharmacodynamics basis of Ephedra herba.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacy, Henan University of Chinese Medicine, Zhengzhou, P. R. China.
- Co-construction Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases by Henan & Education Ministry of Zhengzhou, P. R. China.
- The Engineering and Technology Center for Chinese Medicine Development of Henan Province, Zhengzhou, P. R. China.
ORCID-Profile: Weisheng Feng
Förderung
- National Key Research and Development Program of China
- Youth Science Foundation Project in the National Natural Science Foundation of China
- Henan science and technology development plan-Key R & D and promotion project
- Training plan for young backbone teachers in colleges and universities of Henan province
Zitieren
APA
Cao, Y., Zhou, N., Liu, T., Zhang, J., Wang, Y., Zhang, B., Zhang, Z., Feng, W., & Zheng, X. (2023). Comparative pharmacokinetic studies of Ephedra herba in common cold and nephrotic syndrome rat models. Journal of Separation Science. https://doi.org/10.1002/jssc.202200895
Vancouver
Cao Y, Zhou N, Liu T, Zhang J, Wang Y, Zhang B, et al. Comparative pharmacokinetic studies of Ephedra herba in common cold and nephrotic syndrome rat models. Journal of Separation Science. 2023. doi:10.1002/jssc.202200895
BibTeX
@article{Cao2023,
author = {Cao, Yumin and Zhou, Ning and Liu, Tong and Zhang, Jinying and Wang, Yongxiang and Zhang, Bingxian and Zhang, Zhenkai and Feng, Weisheng and Zheng, Xiaoke},
title = {Comparative pharmacokinetic studies of Ephedra herba in common cold and nephrotic syndrome rat models},
journal = {Journal of Separation Science},
year = {2023},
doi = {10.1002/jssc.202200895}
}
EUVIMED